SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-038910
Filing Date
2023-08-10
Accepted
2023-08-10 07:42:16
Documents
14
Period of Report
2023-08-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc20057297_8k.htm   iXBRL 8-K 28979
2 EXHIBIT 99.1 brhc20057297_ex99-1.htm EX-99.1 169874
6 image1.jpg GRAPHIC 7225
  Complete submission text file 0001140361-23-038910.txt   365182

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atai-20230810.xsd EX-101.SCH 3856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atai-20230810_lab.xml EX-101.LAB 23290
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atai-20230810_pre.xml EX-101.PRE 16546
8 EXTRACTED XBRL INSTANCE DOCUMENT brhc20057297_8k_htm.xml XML 4214
Mailing Address 524 BROADWAY NEW YORK NY 10013
Business Address WALLSTRASSE 16 BERLIN 2M 10179 (617)-699-5876
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

IRS No.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40493 | Film No.: 231157217
SIC: 2834 Pharmaceutical Preparations